search
Back to results

The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema

Primary Purpose

Complications of Diabetes Mellitus

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Combigan
Sponsored by
Meir Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Complications of Diabetes Mellitus focused on measuring Diabetes mellitus, Diabetic macular edema, Intra ocular pressure, Ocular perfusion pressure, Retinal perfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants with a diagnosis of diabetic macular edema over the age of 18 which are eligible to sign an agreement to participate in the study
  • Presence of DME (based on clinical examination of retinal specialist + OCT) in both eyes with an edema thickness ranged from 350 to 800 microns
  • Media lucid enough to allow sufficient quality photographs by OCT

Exclusion Criteria:

  • Patients which do not have a valid diagnosis of DME (Diabetic Macular Edema)
  • Patients with problems that can cause macular edema in any other:

    • Age-Related Macular Degeneration
    • Central retinal vein occlusion (CRVO)/Branch retinal vein occlusion (BRVO) /central retinal artery occlusion (CRAO) / branch retinal artery occlusion (BRAO)
    • Epiretinal membrane (ERM) or Vitreo-macular traction (VMT)
    • Patients who are Pseudophakic in one eye or pseudophakic in both eyes for less than a year
    • Patients treated in order to reduce the DME by intra-vitreal injection or by laser in the past six months
    • Patients which are currently treat with Intra ocular Pressure lowering drops in at least one eye, or have been treated in the past with laser of any kind or with surgery
    • Patients who underwent Pars plana vitrectomy one or both eyes
    • Patients who cannot undergo an OCT examination
    • Patients who want prefer to be treated by the current practices based on clinical judgment
    • Patients with a condition that requires an intervention or laser surgery during the 3 months of study, such as active Proliferative diabetic retinopathy, vitreous hemorrhage or other similar conditions

Sites / Locations

  • Meir Medical centerRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Participants receiving Combigan drops in order to reduce IOP

Arm Description

All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)

Outcomes

Primary Outcome Measures

Change of at least 50 micron in Macular edema
The participants will be examined every month from the time of recruitment as mentioned before, at each visit the Macular Edema will be assessed, but the Outcome measure will be defined as Change of at least 50 Micron in Macular Edema at the third visit, 3 months from recruitment

Secondary Outcome Measures

Full Information

First Posted
March 6, 2016
Last Updated
March 26, 2017
Sponsor
Meir Medical Center
Collaborators
Meir Hospital, Kfar Saba, Israel
search

1. Study Identification

Unique Protocol Identification Number
NCT02718547
Brief Title
The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema
Official Title
The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 26, 2017 (Actual)
Primary Completion Date
March 30, 2018 (Anticipated)
Study Completion Date
July 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Meir Medical Center
Collaborators
Meir Hospital, Kfar Saba, Israel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Investigators propose to examine the effect of lowering the intraocular pressure on macular edema in Participants diagnosed with diabetic macular edema. Our theory is based on the assumption that lower intraocular pressure means higher Ocular Perfusion pressure, which may cause an improvement in retinal perfusion and thus an improvement in retinal oxygenation and reduced edema
Detailed Description
Ocular perfusion pressure (ocular perfusion pressure - OPP), considered the driving force of ocular blood flow. Perfusion pressure is defined as the difference between the artery and vein blood pressure. Because ocular venous pressure is the same or slightly higher than the IOP (intra ocular pressure - IOP), it is common to estimate the OPP as the difference between the arterial blood pressure of IOP. The OPP is critical for diffusion of oxygen, nutrients and metabolic waste from retinal imaging, and decrease it may reduce blood flow to the eye and lead to ischemia or hypoxia. the OPP is controlled by a complex system of Autoregulation. Much has been written about the relationship between the OPP and glaucoma, and agreed that OPP is a low risk factor for this disease. Diabetic macular edema (DME) is the most common cause of vision loss in developed countries the working-age. Many studies were carried out in recent years in an attempt to better understand the pathophysiology of Diabetic macular edema, and there is consensus in the scientific literature that hypertension have a significant effect on Diabetic macular edema. this relationship is much more complex than it seems at first glance. Paques and his team have shown an inverse association between blood pressure to drop night and Diabetic macular edema. LARSEN and his team have shown a similar trend. Hayreh published an article from 2007, where he described the mechanism of improvement of the Diabetic macular edema with discontinuation of hypertensive treatment and thereby raising blood pressure. In this article, Hayreh describes hypoxia as a significant factor in Diabetic macular edema, and demonstrated that treatment of hypoxia by increasing the OPP brought good results in terms of macular thickness If so, it seems that there is not only a link between levels of oxygenation of the retina to Diabetic macular edema, but that improved oxygenation of the retina could lower the levels of macular edema in these patients. If a way were found to improve retinal perfusion, this may lead to an improved oxygenation and reduced edema. The Investigators propose to examine the relationship between macular edema IOP in Participants with Diabetic macular edema, thinking that high IOP means lower OPP, which means increased risk for developing macular edema in this Participants group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Complications of Diabetes Mellitus
Keywords
Diabetes mellitus, Diabetic macular edema, Intra ocular pressure, Ocular perfusion pressure, Retinal perfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Participants receiving Combigan drops in order to reduce IOP
Arm Type
Experimental
Arm Description
All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
Intervention Type
Drug
Intervention Name(s)
Combigan
Other Intervention Name(s)
brimonidine tartrate/timolol maleate ophthalmic solution
Intervention Description
Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
Primary Outcome Measure Information:
Title
Change of at least 50 micron in Macular edema
Description
The participants will be examined every month from the time of recruitment as mentioned before, at each visit the Macular Edema will be assessed, but the Outcome measure will be defined as Change of at least 50 Micron in Macular Edema at the third visit, 3 months from recruitment
Time Frame
Baseline measurement will be conducted at the recruitment of the participant, the second measurement will be preformed after one moth from recruitment and the third and last measurement will be preformed after 3 months from recruitment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants with a diagnosis of diabetic macular edema over the age of 18 which are eligible to sign an agreement to participate in the study Presence of DME (based on clinical examination of retinal specialist + OCT) in both eyes with an edema thickness ranged from 350 to 800 microns Media lucid enough to allow sufficient quality photographs by OCT Exclusion Criteria: Patients which do not have a valid diagnosis of DME (Diabetic Macular Edema) Patients with problems that can cause macular edema in any other: Age-Related Macular Degeneration Central retinal vein occlusion (CRVO)/Branch retinal vein occlusion (BRVO) /central retinal artery occlusion (CRAO) / branch retinal artery occlusion (BRAO) Epiretinal membrane (ERM) or Vitreo-macular traction (VMT) Patients who are Pseudophakic in one eye or pseudophakic in both eyes for less than a year Patients treated in order to reduce the DME by intra-vitreal injection or by laser in the past six months Patients which are currently treat with Intra ocular Pressure lowering drops in at least one eye, or have been treated in the past with laser of any kind or with surgery Patients who underwent Pars plana vitrectomy one or both eyes Patients who cannot undergo an OCT examination Patients who want prefer to be treated by the current practices based on clinical judgment Patients with a condition that requires an intervention or laser surgery during the 3 months of study, such as active Proliferative diabetic retinopathy, vitreous hemorrhage or other similar conditions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nimrod Dar, MD
Phone
+972545937757
Email
nimrod.dar@gmail.com
Facility Information:
Facility Name
Meir Medical center
City
Kfar Saba
ZIP/Postal Code
69419
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nimrod Dar, MD
Phone
+972545937757
Email
nimrod.dar@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
8361399
Citation
Glucksberg MR, Dunn R. Direct measurement of retinal microvascular pressures in the live, anesthetized cat. Microvasc Res. 1993 Mar;45(2):158-65. doi: 10.1006/mvre.1993.1015.
Results Reference
background
PubMed Identifier
20868686
Citation
Schmidl D, Garhofer G, Schmetterer L. The complex interaction between ocular perfusion pressure and ocular blood flow - relevance for glaucoma. Exp Eye Res. 2011 Aug;93(2):141-55. doi: 10.1016/j.exer.2010.09.002. Epub 2010 Sep 22.
Results Reference
background
PubMed Identifier
23419295
Citation
Thomas BJ, Shienbaum G, Boyer DS, Flynn HW Jr. Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol. 2013 Feb;48(1):22-30. doi: 10.1016/j.jcjo.2012.11.012.
Results Reference
background
PubMed Identifier
8366905
Citation
Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med. 1993 Sep 30;329(14):1035-6. doi: 10.1056/NEJM199309303291410. No abstract available.
Results Reference
background
PubMed Identifier
7831044
Citation
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7-16. doi: 10.1016/s0161-6420(95)31052-4.
Results Reference
background
PubMed Identifier
19171208
Citation
Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32. doi: 10.1016/j.survophthal.2008.10.001.
Results Reference
background
PubMed Identifier
15534123
Citation
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004 Nov;122(11):1631-40. doi: 10.1001/archopht.122.11.1631.
Results Reference
background
PubMed Identifier
16303968
Citation
Paques M, Massin P, Sahel JA, Gaudric A, Bergmann JF, Azancot S, Levy BI, Vicaut E. Circadian fluctuations of macular edema in patients with morning vision blurring: correlation with arterial pressure and effect of light deprivation. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4707-11. doi: 10.1167/iovs.05-0638.
Results Reference
background
PubMed Identifier
15980216
Citation
Larsen M, Wang M, Sander B. Overnight thickness variation in diabetic macular edema. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2313-6. doi: 10.1167/iovs.04-0893.
Results Reference
background
PubMed Identifier
17876597
Citation
Hayreh SS. Role of retinal hypoxia in diabetic macular edema: a new concept. Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):353-61. doi: 10.1007/s00417-007-0678-2. Epub 2007 Sep 18.
Results Reference
background
PubMed Identifier
22890599
Citation
Vinten M, La Cour M, Lund-Andersen H, Larsen M. Acute effect of pure oxygen breathing on diabetic macular edema. Eur J Ophthalmol. 2012 Aug 8:0. doi: 10.5301/ejo.5000195. Online ahead of print.
Results Reference
background
PubMed Identifier
14744906
Citation
Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):617-24. doi: 10.1167/iovs.03-0557.
Results Reference
background
PubMed Identifier
19094166
Citation
Vinten M, la Cour M, Lund-Andersen H, Larsen M. Effect of acute postural variation on diabetic macular oedema. Acta Ophthalmol. 2010 Mar;88(2):174-80. doi: 10.1111/j.1755-3768.2008.01421.x. Epub 2009 Dec 13.
Results Reference
background
PubMed Identifier
16538448
Citation
Frederiksen CA, Jeppesen P, Knudsen ST, Poulsen PL, Mogensen CE, Bek T. The blood pressure-induced diameter response of retinal arterioles decreases with increasing diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1255-61. doi: 10.1007/s00417-006-0262-1. Epub 2006 Mar 15.
Results Reference
background

Learn more about this trial

The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema

We'll reach out to this number within 24 hrs